EPB41L5

Across TCGA pan-cancer cohorts, EPB41L5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EPB41L5 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher EPB41L5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EPB41L5 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

CESC, LUSC, and CHOL are the cancer types where EPB41L5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.193	0.740	.010	12	view →
LUSC	OS	Median	II,III,IV	0.226	0.633	.008	12	view →
CHOL	OS	Median	All	0.089	0.727	.001	9	view →
STAD	DFS	Median	III,IV	1.000	0.337	.041	8	view →
PRAD	DFS	Median	All	0.213	0.775	.025	4	view →
COAD	DFS	Median	All	0.125	0.559	.044	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EPB41L5–CESC (DFS)

Open the CESC breakdown →